Australia's most trusted
source of pharma news
Friday, 13 March 2026
Posted 13 March 2026 AM
Gilead has failed in a bid to protect $164 million in reimbursements from taking a follow-on statutory price reduction haircut, with a court ruling in favour of the Minister for Health.
The pharma took action last December when it looked like Alphapharm would list Dencovir - a generic version of Gilead's HIV treatment and prophylactic Descovy - on the ARTG. Dencovir secured TGA approval in January.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.